CIK 0001488039 · Non-accelerated filer<br>Smaller reporting company
ATOSSA THERAPEUTICS, INC.
Sign in to watch- Ticker
- ATOS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 264753208
- Phone
- 206.588.0256
- Business address
- 1448 NW MARKET STREET, SUITE 500, SEATTLE, WA, 98107
- Former names
- ATOSSA GENETICS INC
- DEF 14A Proxy Proxy Statement
- 4 Open-market buy Director bought 1,500 shares at $0.33 ($495)
- PRE 14A Proxy Proxy Statement (Preliminary)
- 8-K Event Results of operations
- 10-K Report Annual Report
- 4 Open-market buy Director bought 15,000 shares at $0.37 ($5,550)
- 4 Open-market buy President & CEO bought 15,000 shares at $0.37 ($5,550)
- 4 Open-market buy President & CEO bought 15,000 shares at $0.53 ($7,950)
- 4 Open-market buy Director bought 15,000 shares at $0.53 ($7,950)
- 8-K Event Material agreement · Executive or director change
- 8-K Event Regulation FD disclosure · Other events
- SC 13D/A Stake Beneficial Ownership Report
- 4 Open-market buy Director bought 50,000 shares at $0.20 ($10,000)
- 4 Open-market buy President & CEO bought 50,000 shares at $0.20 ($10,000)
- 424B3 Offering Prospectus
- EFFECT Other Notice of Effectiveness
- S-1/A Offering Registration Statement
- 8-K Event Material agreement · Acquisition or sale completed
- CORRESP Other Correspondence Between Filers and SEC Staff
- UPLOAD Other SEC-generated Letter
Page 22 of 33 · 643 filings